Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues [Abstract]
Revenue		$ 43,190	$ 48,926	$ 85,063	$ 86,573
Operating expenses
Cost of revenue		19,317	17,910	37,368	36,591
Research and development		25,353	32,237	55,598	64,838
Sales and marketing		20,314	23,872	42,633	46,180
General and administrative		17,895	22,302	37,492	43,133
Amortization of intangible assets		424	423	847	842
Impairment of long-lived assets	[1]	7,205		7,205
Total operating expenses		90,508	96,744	181,143	191,584
Loss from operations		(47,318)	(47,818)	(96,080)	(105,011)
Interest and other income, net		3,766	3,612	7,988	6,636
Interest expense	[2]	(2,696)	(3,605)	(5,689)	(7,136)
Net loss		(46,248)	(47,811)	(93,781)	(105,511)
Add: Net loss attributable to noncontrolling interest		26	1	52	2
Net loss attributable to Adaptive Biotechnologies Corporation		$ (46,222)	$ (47,810)	$ (93,729)	$ (105,509)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic		$ (0.31)	$ (0.33)	$ (0.64)	$ (0.73)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic		147,414,095	144,397,693	146,600,811	143,956,867
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted		$ (0.31)	$ (0.33)	$ (0.64)	$ (0.73)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted		147,414,095	144,397,693	146,600,811	143,956,867

[1] Represents expenses recognized in conjunction with restructuring activities. See Note 12, Restructurings for details on our restructuring expenses.

[2] Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 8, Revenue Interest Purchase Agreement for details on the Purchase Agreement.